News stories about Aclaris Therapeutics (NASDAQ:ACRS) have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aclaris Therapeutics earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.6007487882703 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Several research firms recently commented on ACRS. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Aclaris Therapeutics in a research report on Tuesday, November 7th. Zacks Investment Research cut shares of Aclaris Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. ValuEngine cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, September 12th. JMP Securities reissued an “outperform” rating and set a $39.00 price target on shares of Aclaris Therapeutics in a research report on Friday, September 8th. Finally, BidaskClub raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 16th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $39.20.
Shares of Aclaris Therapeutics (ACRS) traded up $0.09 during trading hours on Friday, reaching $22.11. 284,300 shares of the company’s stock traded hands, compared to its average volume of 279,880. Aclaris Therapeutics has a 52-week low of $21.32 and a 52-week high of $33.25.
Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.23. The business had revenue of $0.68 million for the quarter, compared to the consensus estimate of $2.00 million. sell-side analysts anticipate that Aclaris Therapeutics will post -2.59 earnings per share for the current fiscal year.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.